Singapore General Hospital

What Singapore General Hospital does

Singapore General Hospital (SGH) is Singapore's largest and oldest public hospital, founded in 1821 and operating as the flagship tertiary and quaternary referral centre of the SingHealth cluster (Singapore Health Services, a government state entity). It delivers multidisciplinary medical care across more than 30 clinical specialties on the SGH Campus at Outram Road, co-located with five national specialty centres — National Cancer Centre Singapore, Singapore National Eye Centre, National Heart Centre Singapore, National Dental Centre Singapore, and National Neuroscience Institute — together with Outram Community Hospital and the Academia research and education complex. SGH runs a 130+-surgeon Division of Surgery & Surgical Oncology spanning 13 subspecialties, an emergency department, outpatient specialist clinics, inpatient wards, maternity services accredited under the Baby-Friendly Hospital Initiative, and the Healthier EAST@SG population health programme serving 610,000 eastern Singapore residents.

The hospital's technology stack centres on proprietary AI diagnostics and clinical research translation. Key assets include PENSIEVE-AI (tablet-drawing cognitive assessment, 93% accuracy on ~1,800 seniors, sub-five-minute assessment), iACT (180-combination antibiotic selection AI, 84 clinical uses over three years, targeted for export to Southeast Asia and Greater China), AI-integrated MRI workflows via Philips (15–50% scan-time reduction), AI-assisted chest radiograph models, 3D-printed and virtually planned shoulder replacements, and the HALT histotripsy liver-cancer trial — the only such trial in Southeast Asia focused on Asian patients. Patient-facing digital channels include the Health Buddy app, video consultation, medication delivery, MyCare bedside tablets, the MySurgery app, and a Digital Medical Certificate service.

Commercially, SGH operates on a publicly regulated model: charges follow MOH fee benchmarks with subsidised and unsubsidised tiers, payable via MediSave, MediShield Life, and other national schemes. Revenue is supplemented by research grants (notably the $12M HALT trial funded by Li Ka Shing Foundation and Temasek Trust, and the $9M Renalssance palliative-care programme funded by Lien Foundation). The go-to-market is effectively direct-to-patient via self-referral, GP referrals, inter-hospital transfers, and SingHealth polyclinics, augmented by strategic commercialisation partnerships — Redesign Health for digital health startup co-creation, A*STAR's Diagnostics Development Hub for AI diagnostics market-readiness, and Vivo Surgical for endoscopic robotics. Pricing is per-transaction against MOH schedules, with no publicly disclosed revenue figures.

Name

Singapore General Hospital

Legal name

Singapore General Hospital Pte Ltd

Website

https://sgh.com.sg

Company type

Private

Founded year

1821

Operating status

Operating

Headcount range

251–500 employees

Short description

Singapore General Hospital is Singapore's largest public tertiary and quaternary referral hospital within the SingHealth cluster, delivering multidisciplinary care across 30+ specialties to general patients, seniors, cancer patients, and expectant mothers. It runs proprietary AI diagnostics (PENSIEVE-AI, iACT) and is co-located with five national specialty centres.

Ownership category

akta.pro rank

Product category

Public Hospital Services

NAICS

General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Community & Regional General Hospitals (HLAFAAAB)

akta.pro secondary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Public hospital services
• Tertiary medical care
• Specialist clinical services
• Acute hospital care
• Academic medical center

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Patient Care Services: SGH generates revenue through providing inpatient and outpatient medical services to patients, billed according to MOH fee benchmarks. Patients can pay using MediSave, MediShield Life, and other national healthcare schemes.
2. Research Grants and Clinical Trials: SGH participates in funded research programs and clinical trials, supported by government agencies, foundations, and trusts. Examples include the $12 million HALT histotripsy trial (Li Ka Shing Foundation, Temasek Trust) and the $9 million Renalssance palliative care program (Lien Foundation).

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Singapore General Hospital is Singapore's largest and oldest public hospital, providing multidisciplinary tertiary and quaternary medical care across 30+ clinical specialties at its SGH Campus. It delivers inpatient and outpatient services, emergency care, surgical oncology, maternity care, and chronic disease management, integrating clinical care with research and education as part of the SingHealth Duke-NUS Academic Medical Centre. The hospital supports digital patient services including the Health Buddy mobile app, video consultations, digital medical certificates, and medication delivery.

Product overview

Singapore General Hospital offers a comprehensive digital health portfolio consisting of AI-powered diagnostic tools, patient-facing mobile applications, and specialized medical technologies. The core AI offerings include PENSIEVE-AI for cognitive assessment and iACT for antibiotic optimization. These are complemented by patient-facing digital services including the Health Buddy App, video consultations, digital medical certificates, and medication delivery. SGH also operates specialized facilities including a Philips MRI Training Center with AI-integrated workflows and serves as a Centre of Excellence for the ERES endoscopic surgical robot. The hospital's digital ecosystem connects patients to services through mobile apps, bedside tablets, and online portals, while advanced surgical planning utilizes 3D printing and virtual planning technologies.

Differentiator

Problem solved

Functional benefit

Brands

• PENSIEVE-AI: AI-powered tool that uses patients' tablet drawings to detect cognitive impairment and dementia with 93 percent accuracy
• iACT
• Health Buddy App

Products and services

• PENSIEVE-AI AI-powered cognitive assessment tool that uses patients' tablet drawings to detect cognitive impairment and dementia with 93 percent accuracy among seniors aged 65 and older, completing assessments in under five minutes.
• iACT (Intelligent Antibiotic Combination Test) AI-powered test kit that helps doctors determine the most effective antibiotic combinations for drug-resistant infections, using 180 proprietary antibiotic combinations with AI predictive software to generate personalized reports.
• Health Buddy App

Quantifiable outcome

• PENSIEVE-AI detects cognitive impairment with 93% accuracy in 1,800 seniors aged 65+, completing assessments in under 5 minutes, saving SG$3,650 per senior in testing costs and 15 hours of clinician time per patient.
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability12 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• National Kidney Foundation SingaporecoreStrategic or Co-development Partner · 1 June 2026Lead organization in the $9 million Renalssance pilot programme, partnering with SGH and two other major Singapore public hospitals to integrate palliative care earlier into advanced chronic kidney disease treatment. Expected to benefit over 5,260 patients over four years, supported by Lien Foundation.
• National Cancer Centre SingaporecoreStrategic or Co-development Partner · 1 June 2026SGH's partner in the HALT histotripsy liver cancer trial and part of the broader SingHealth cluster on SGH Campus, collaborating on cancer research and treatment.
• A*STAR Diagnostics Development HubcoreTechnology or Integration · 20 May 2026Partnership between SGH and A*STAR's Diagnostics Development Hub signed at the SingHealth AI in Health Symposium during ATxSummit 2026. Aims to accelerate AI-enabled diagnostic solutions into market-ready products, building on existing iACT collaboration.
• Bhutan's Gyalpozhing College of Information TechnologyminorStrategic or Co-development Partner · 20 May 2026MOU signed between SingHealth and Bhutan's Gyalpozhing College of Information Technology for an AI-assisted chest radiograph model deployment.
• Vivo SurgicalcoreStrategic or Co-development Partner · 6 December 2025Landmark MOU establishing SGH as a Centre of Excellence for the ERES endoscopic surgical robot. The collaboration brings together surgeons, engineers and researchers to validate the technology and integrate it into clinical workflows, making advanced endoluminal procedures more accessible.
• Redesign Health Inc.coreStrategic or Co-development Partner · 1 December 2025Three-year collaboration (formalized via MOU signed December 2025) to co-develop digital health startups. Combines SGH's clinical expertise and hospital access with Redesign Health's institutional capital, AI-enabled platform, and domain expertise. Addresses ageing-in-place, chronic care management, workforce productivity, and national healthcare priorities across Asia and globally.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 September 2025SingHealth (parent organization of SGH) was inducted into the WHO Global Network for Age-friendly Cities and Communities in September 2025 and received the His Highness Sheikh Sabah Al-Ahmad Al-Jaber Al-Sabah Prize for the Promotion of Healthy Ageing at the WHO Assembly in Geneva in May 2026.
• PhilipscoreTechnology or IntegrationSGH partnered with Philips to establish an MRI Training Center featuring AI-integrated workflows that can reduce scan times by 15 to 50 percent, with plans to extend training across Asia Pacific.
• Duke-NUS Medical SchoolcoreStrategic or Co-development PartnerSGH collaborates with Duke-NUS Medical School on research and medical education. Joint research published in The Lancet Digital Health on AI in medical education. Also collaborated on exercise-cancer research published in Nature Communications.
• Tsinghua UniversityminorStrategic or Co-development PartnerCollaborated with SGH and Duke-NUS on a study published in The Lancet Digital Health exploring the potential of AI in transforming medical education.
• Cardiff UniversityminorStrategic or Co-development PartnerInternational research collaborator with SGH and Duke-NUS on a study published in Nature Communications discovering how physical activity may help protect older adults against cancer.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Changi General Hospital: Public acute hospital under SingHealth that shares the SingHealth cluster affiliation with SGH but serves the eastern region. Comparable in clinical breadth, public-sector governance, and SingHealth digital integration, though secondary in tertiary complexity.
• National University Hospital (NUH): Singapore's other major public academic hospital, part of the National University Health System cluster. Directly comparable as a public tertiary/quaternary referral centre with academic medical centre status, competing head-to-head with SGH in clinical excellence, research output, and specialist care on the opposite side of Singapore.
• Tan Tock Seng Hospital: Major public tertiary hospital within Singapore's National Healthcare Group cluster. Comparable as a public-sector tertiary referral centre with strong AI/digital health initiatives (e.g., Centre for Healthcare Innovation) and a broad specialty footprint serving central Singapore.
• KK Women's and Children's Hospital: SingHealth-affiliated public hospital specializing in obstetrics, gynaecology, paediatrics, and neonatology. Directly comparable as part of the same SingHealth cluster, sharing governance, IT systems (Health Buddy), and patient referral patterns with SGH's O&G department.

Broad incumbents

• Raffles Hospital: Major Singapore private tertiary hospital under Raffles Medical Group. Comparable as a multi-specialty tertiary hospital with regional medical tourism appeal and academic/teaching affiliations, though operating on a private pricing model across much broader specialty coverage.
• Mayo Clinic: US-based global benchmark academic medical centre and integrated delivery network. Comparable as a leading tertiary/quaternary academic medical centre that integrates AI diagnostics, clinical research, and complex specialty care; an aspirational peer in clinical reputation and AI-in-healthcare thought leadership.
• Mount Elizabeth Hospital (Singapore): Singapore's flagship private tertiary hospital under IHH Healthcare, focused on premium specialist care and medical tourism. Comparable in tertiary complexity and Asian medical-tourism positioning, but operates on a private pricing model absent the public-sector price regulation that constrains SGH.

Regional players

• Cleveland Clinic Abu Dhabi: US-branded academic medical centre in the UAE, modelled after and operated by Cleveland Clinic. Comparable to SGH as an academic tertiary/quaternary medical centre aiming to anchor medical tourism for the wider region (Gulf vs. Southeast Asia) and integrate AI/advanced diagnostics into clinical workflows.
• Bumrungrad International Hospital: Thailand-based international tertiary hospital treating large volumes of international patients. Comparable as a Southeast Asian tertiary referral centre with strong medical-tourism positioning, although operating on a private pricing structure rather than public fee benchmarks.

Emerging players

• Apollo Hospitals: India's largest private hospital chain with tertiary/quaternary multi-specialty services, AI diagnostics partnerships, and medical tourism focus. Comparable as a high-volume tertiary provider in Asia pursuing AI-driven diagnostics and cross-border patient care, though structured as a publicly listed private chain.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/mysgh
• YouTubeyoutube.com/user/mysghonline
• Facebookfacebook.com/SingaporeGeneralHospital
• LinkedInlinkedin.com/company/singapore-general-hospital
• Instagraminstagram.com/sghseen

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singapore General Hospital